Gene edit­ing stocks get bush­whacked as new stud­ies high­light CRISPR/Cas9 can­cer risks

Gene edit­ing stocks have a habit of run­ning up and down when some new piece of re­search un­der­scores their po­ten­tial or the risks as­so­ci­at­ed with the tech.

To­day the num­bers were plung­ing in­to the red for CRISPR Ther­a­peu­tics $CR­SP, In­tel­lia $NT­LA and Ed­i­tas $ED­IT as some top-lev­el in­ves­ti­ga­tors spot­light­ed a con­nec­tion be­tween CRISPR-Cas9 and an added risk of can­cer as­so­ci­at­ed with the tech­nol­o­gy. And soon af­ter the stud­ies hit, the biotechs in­volved be­gan to strike back at the re­searchers’ con­clu­sions.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN